Wegovy® (semaglutide) explained — how it works, who it’s for, dosing, weight management, side effects, serious warnings, and what to discuss with your healthcare professional. Wegovy® (semaglutide) has become one of the most discussed medications for chronic weight management. But how does it actually work inside the body — and what should you know before considering treatment? In this episode of Rehealthify Diabetes Corner, we take a closer look at Wegovy and explain how semaglutide interacts with GLP-1 receptors involved in appetite regulation, food intake, glucose regulation, and weight management. We also cover how Wegovy is used, how doses are gradually increased, what happens when treatment is missed or restarted, common side effects, serious adverse reactions, the boxed warning concerning thyroid C-cell tumors, and important questions to discuss with a qualified healthcare professional. The goal is simple: make the science easier to understand so you can have a more informed conversation about your health. In this video, you'll learn: • What Wegovy® (semaglutide) is • How semaglutide works as a GLP-1 receptor agonist • How Wegovy can affect appetite and food intake • How Wegovy is used for chronic weight management • Wegovy dosing and dose escalation • The current 7.2 mg Wegovy HD option for certain adults • What happens when a dose is missed • How semaglutide affects appetite and glucose regulation • What to know about common side effects • Serious adverse reactions and when to seek medical attention • Wegovy's boxed warning about thyroid C-cell tumors • Important contraindications and medication considerations • What questions to discuss with your healthcare professional Chapters 00:00 — Wegovy® & Semaglutide: What Is It? 00:40 — Who Is Wegovy For? 01:20 — Wegovy & Cardiovascular Risk 01:50 — Important Safety Warnings 02:30 — Wegovy at a Glance 03:20 — When to Seek Medical Attention 03:30 — How Wegovy Is Taken 03:50 — Wegovy Dosing & Dose Escalation 04:30 — Missed Doses & Restarting Treatment 04:50 — How Semaglutide Works 05:40 — Appetite, Food Intake & Weight Management 06:20 — Is Wegovy Working? 07:10 — Contraindications, Warnings & Medication Considerations 07:20 — Questions to Discuss With Your Healthcare Professional 07:30 — Rehealthify Diabetes Corner Important Safety Information Wegovy® (semaglutide) carries a boxed warning regarding the risk of thyroid C-cell tumors. In animal studies, semaglutide caused thyroid C-cell tumors; it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in people with a personal or family history of MTC or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy also has warnings and precautions concerning conditions including pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and pulmonary aspiration during general anesthesia or deep sedation. Common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, dizziness, fatigue and other gastrointestinal symptoms. This video is for educational and informational purposes only. It is not medical advice and does not replace advice from a qualified healthcare professional. Do not start, stop, change, or restart a prescription medication based solely on information presented in this video. If you are considering Wegovy or are currently taking it, talk with your healthcare professional about whether it is appropriate for you, your medical history, other medications, and your individual treatment goals. References & Sources U.S. Food and Drug Administration (FDA) Wegovy® (semaglutide) Prescribing Information, revised March 2026. U.S. Food and Drug Administration (FDA) FDA approval information regarding Wegovy and cardiovascular risk reduction in adults with cardiovascular disease and overweight or obesity. National Library of Medicine — MedlinePlus Semaglutide Injection: Drug Information, revised May 15, 2026. About Rehealthify Rehealthify is an independent health-information and education media channel focused on making complex health topics easier to understand. Subscribe to Rehealthify Diabetes Corner for clear, science-focused videos about diabetes, weight management, medications, metabolic health, and the questions people are asking about today's most discussed treatments. Educational purposes only. Not medical advice. Consult a qualified healthcare professional about your health. #wegovy #semaglutide #weightloss #weightmanagement #glp1 #wegovyhd #obesity #health #rehealthify #semaglutideweightloss #wegovyjourney #wegovyweightloss #semaglutideforweightloss